AdAlta Limited (1AD.AX)
AUD 0.02
(-6.25%)
AUD 0.02
(-6.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -5.3 Million AUD | -9.53% |
| 2023 | -4.84 Million AUD | -39.3% |
| 2022 | -5.96 Million AUD | -10.7% |
| 2021 | -5.38 Million AUD | 7.05% |
| 2020 | -5.79 Million AUD | 38.94% |
| 2019 | -5.95 Million AUD | -61.51% |
| 2018 | -3.85 Million AUD | -22.61% |
| 2017 | -2.99 Million AUD | -151.12% |
| 2016 | -1.17 Million AUD | -44.65% |
| 2015 | -1.31 Million AUD | -5.79% |
| 2014 | -1.24 Million AUD | -64.38% |
| 2013 | -759.06 Thousand AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | 15.78% |
| 2024 Q4 | -2.36 Million AUD | 0.0% |
| 2024 Q2 | -4.07 Million AUD | 0.0% |
| 2023 Q4 | -4.42 Million AUD | 0.0% |
| 2023 FY | - AUD | -39.3% |
| 2023 Q2 | -3.88 Million AUD | 0.0% |
| 2022 Q4 | -2.39 Million AUD | 0.0% |
| 2022 Q2 | -3.57 Million AUD | 0.0% |
| 2022 FY | - AUD | -10.7% |
| 2021 Q4 | -4.1 Million AUD | 0.0% |
| 2021 Q2 | -4.33 Million AUD | 0.0% |
| 2021 FY | - AUD | 7.05% |
| 2020 Q2 | -6.04 Million AUD | 0.0% |
| 2020 Q4 | 245.44 Thousand AUD | 0.0% |
| 2020 FY | - AUD | 38.94% |
| 2019 FY | - AUD | -61.51% |
| 2019 Q2 | -3.6 Million AUD | 0.0% |
| 2019 Q4 | -2.35 Million AUD | 0.0% |
| 2018 Q4 | -492.38 Thousand AUD | 0.0% |
| 2018 Q2 | -3.36 Million AUD | 0.0% |
| 2018 FY | - AUD | -22.61% |
| 2017 Q2 | -2.26 Million AUD | 0.0% |
| 2017 FY | - AUD | -151.12% |
| 2017 Q4 | -732.65 Thousand AUD | 0.0% |
| 2016 Q1 | -344.02 Thousand AUD | 0.0% |
| 2016 Q4 | -483.22 Thousand AUD | 0.0% |
| 2016 Q2 | -688.05 Thousand AUD | -100.0% |
| 2016 FY | - AUD | -44.65% |
| 2015 FY | - AUD | -5.79% |
| 2014 FY | - AUD | -64.38% |
| 2013 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 151.108% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -264.03% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 85.449% |
| Biome Australia Limited | -1.57 Million AUD | -235.986% |
| Patrys Limited | -3.49 Million AUD | -51.846% |
| Orthocell Limited | -11.68 Million AUD | 54.605% |
| Imugene Limited | -147.97 Million AUD | 96.417% |
| Noxopharm Limited | -5.94 Million AUD | 10.811% |
| PYC Therapeutics Limited | -38.11 Million AUD | 86.089% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 53.073% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 26.205% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 32.769% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 46.708% |
| CSL Limited | 4.73 Billion AUD | 100.112% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 39.968% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -78.243% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 110.224% |
| Starpharma Holdings Limited | -12.57 Million AUD | 57.838% |
| Nanollose Limited | -1.14 Million AUD | -361.948% |
| Memphasys Limited | -3.3 Million AUD | -60.313% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -636.035% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -195.204% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -16.298% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 61.904% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -88.165% |
| Race Oncology Limited | -14.2 Million AUD | 62.666% |
| Nyrada Inc. | -4.59 Million AUD | -15.371% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 123.089% |
| Dimerix Limited | -24.95 Million AUD | 78.754% |
| PharmAust Limited | -9.45 Million AUD | 43.897% |
| Immutep Limited | -42.87 Million AUD | 87.632% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 88.123% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 72.906% |
| BTC Health Limited | 1.05 Million AUD | 602.489% |
| Acrux Limited | -7.93 Million AUD | 33.14% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 102.661% |
| Biotron Limited | -5.04 Million AUD | -5.211% |
| Tissue Repair Ltd | -5.77 Million AUD | 8.178% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 88.314% |
| Hexima Limited | -995.54 Thousand AUD | -432.644% |
| AnteoTech Limited | -11.57 Million AUD | 54.172% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 91.784% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 75.168% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -63.537% |
| Actinogen Medical Limited | -12.92 Million AUD | 58.961% |
| Immuron Limited | -6.19 Million AUD | 14.367% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -179.444% |